UTHR
United Therapeutics Corporation · Healthcare · Biotechnology
Momentum inputs (comparable managers): holder breadth 0.0% · share flow -6.0% · net new positions 0.0% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 86.02K | $43.82M | n/a | n/a |
| Q2 2026 | 157 | +4 | 27.98M | $15.17B | +8 | −5 |
| Q1 2026 | 157 | -1 | 29.64M | $17.54B | +5 | −7 |
| Q4 2025 | 157 | +1 | 32.29M | $15.72B | +2 | n/a |
| Q3 2025 | 21 | 0 | 20.11M | $8.43B | +1 | −2 |
| Q2 2025 | 19 | 0 | 20.17M | $5.79B | n/a | n/a |
| Q1 2025 | 16 | +1 | 10.14M | $3.12B | +1 | n/a |
| Q4 2024 | 15 | 0 | 10.52M | $3.71B | +1 | −1 |
| Q3 2024 | 14 | 0 | 8.99M | $3.22B | n/a | n/a |
| Q2 2024 | 14 | n/a | 8.17M | $2.60B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 2.46M | -22.3% | $869.36M | 0.2% | ▼ Trim | 3 | SEC ↗ ×9 |
| 2 | State Street Global Advisors ✦ (passive) | 2.20M | n/a | $776.30M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Renaissance Technologies ✦ | 2.09M | -3.1% | $737.22M | 1.1% | ▼ Trim | 3 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 1.14M | +4.0% | $401.18M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 5 | AQR Capital Management ✦ | 975.44K | +0.8% | $344.18M | 0.4% | ▲ Add | 3 | SEC ↗ ×6 |
| 6 | Arrowstreet Capital ✦ | 542.45K | -15.4% | $191.40M | 0.2% | ▼ Trim | 3 | SEC ↗ |
| 7 | Norges Bank ✦ (passive) | 430.12K | +1.5% | $151.76M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 8 | T. Rowe Price ✦ | 397.88K | +15.5% | $140.39M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 9 | Bridgewater Associates ✦ | 107.73K | +74.5% | $38.01M | 0.2% | ▲ Add | 3 | SEC ↗ |
| 10 | Gotham Asset Management ✦ | 61.18K | +17.5% | $21.59M | 0.2% | ▲ Add | 3 | SEC ↗ |
| 11 | D. E. Shaw & Co. ✦ | 43.29K | -16.0% | $15.27M | 0.0% | ▼ Trim | 3 | SEC ↗ ×2 |
| 12 | Millennium Management ✦ | 28.06K | +210.2% | $9.90M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 13 | Citadel Advisors ✦ | 20.34K | New | $7.18M | 0.0% | New | 1 | SEC ↗ ×2 |
| 14 | Fisher Asset Management ✦ | 16.34K | +159.1% | $5.77M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 15 | Two Sigma Investments ✦ | 1.77K | +3.0% | $625,585 | 0.0% | ▲ Add | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Citadel Advisors | $7.18M | 0.0% |
Exited
| Marshall Wace | $4.55M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 844 holders, 41.22M shares, $23.10B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 401 sh · $215,959
Officer, Director · 391 sh · $212,185
Officer, Director · 40 sh · $21,754
Officer, Director · 239 sh · $128,964
Officer, Director · 535 sh · $286,582
Officer, Director · 760 sh · $408,681
Officer, Director · 1.02K sh · $544,296
Officer, Director · 1.82K sh · $969,579
Officer, Director · 240 sh · $127,314
Officer, Director · 2.38K sh · $1.27M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology